CME Webcast Teaches on Preventive Cardiology

OSUWexnerbloglogo2014 CME Webcast Teaches on Preventive Cardiology. The best way to improve outcomes in cardiovascular disease is to not get it in the first place and today on MedNet21, we are going to show you what you can do to prevent heart disease in your patients. Let me welcome today’s guests. Dr. Wesley Milks is a cardiologist and Assistant Professor of Internal Medicine and Kelly Bartsch is a pharmacist specializing in lipid management.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: REVIEW
the mechanisms of action of the major medication classes utilized in the 2018 multi-society cholesterol guidelines; and UNDERSTAND the influence of the new cardiovascular outcomes trials for ezetimibe and the PCSK9 inhibitors on the new cholesterol guidelines; DEMONSTRATE understanding of key atherosclerotic risk and risk-enhancing factors as well as of recent pivotal lipid lowering treatment guidelines; and SELECT the appropriate target of lipid lowering therapy (e.g. LDL-C or non-HDL-C) with respect to the patient’s comorbid metabolic conditions.

You’ll also learn about the following:

  • Cholesterol level goals
  • Indications for medical treatment of lipids
  • Follow-up of patients started on cholesterol lowering drugs
  • Monitoring of cholesterol lowering drugs
  • CRP and other inflammatory markers

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Learn About New Therapies for Type 2 Diabetes

OSUWexnerbloglogo2014 Learn About New Therapies for Type 2 Diabetes. 25 years ago, the management of type II diabetes was easy. You started a patient on a sulfonylurea and then if their glucose level didn’t improve, you added in NPH insulin. But things have changed. And today, we have better and safer medications to treat diabetes. Which is a good thing because the prevalence of diabetes over the past 25 years has grown enormously and we really needed new treatments to fight against this public health threat. But with new treatments can come confusion about which to use in different clinical situations. Joining our moderator on this CME webcast, to update us on the management of type 2 diabetes is endocrinologist and Assistant Professor of Internal Medicine from the Ohio State University, Dr. Joshua Joseph.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: DESCRIBE the role of new medical therapies in hypoglycemia; and DESCRIBE the role of new medical therapies in cardiovascular disease.

You’ll also learn about the following:

  • New directions in the treatment of type 2 diabetes
  • Hemoglobin A1C targets
  • Treatment of type 2 diabetes when medication cost is a consideration
  • New glucose monitoring technologies

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Discover Device Therapies for Heart Failure on Webcast

OSUWexnerbloglogo2014 Discover Device Therapies for Heart Failure on Webcast. In the past, we could prescribe medications or do a heart transplant, but that was about it. Now we have new devices that can help our patients with heart failure. On this CME webcast, we’re going to hear about these new devices to show you how these treatments can help them live longer and better lives. Joining our moderator in the studio are cardiologists and heart failure experts from the Ohio State University. Dr. Rami Kahwash is an Associate Professor of Internal Medicine and he is the Director of the Cardiovascular Research Organization at OSU. And Dr. Sitaramesh Emani is an Assistant Professor of Internal Medicine and the Director of Heart Failure Clinical Trials.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: DESCRIBE the primary prevention strategies of the prevention of sudden cardiac death in chronic systolic heart failure and the role of Cardiac Resynchronization therapy (CRT); and UNDERSTAND indications of the new defibrillation strategies (wearable ICD and subcutaneous ICD) in the prevention of sudden cardiac death.

You’ll also learn about the following:

  • Medications versus implantable cardiac defibrillators
  • Implantable cardiac monitoring devices
  • Precautions when caring for patients with a ventricular assist device
  • Complications of ventricular assist devices
  • Investigational devices
  • Current role of the intra-aortic balloon pump

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Watch On-line CME Webcast About Uncontrolled Diabetes

OSUWexnerbloglogo2014 Watch On-line CME Webcast About Uncontrolled Diabetes. Hemoglobin A1C measurement is a test that you likely use in your practice every day and when the hemoglobin A1C is very high, it is a sign that the patient’s diabetes has been poorly controlled. On this CME Webcast, we’re going to discuss uncontrolled diabetes. First, to tell us about the medical management of uncontrolled diabetes, endocrinologist and Associate Professor of Internal Medicine, Dr. Kathleen Dungan. And then tell us about the role of diabetic education, nurse and OSU diabetic educator, Janet Zappe.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: COMPARE and contrast the mechanisms of action, efficacy, side effects, and contra-indications of glucose lowering agents for type 2 diabaetes; and UNDERSTAND how to intensify glucose lowering agents to meet individualized patient targets.

You’ll also learn about the following:

  • The ideal hemoglobin A1C level
  • The role of the diabetes educator
  • When to refer
  • Home glucose monitoring
  • Incorporating diabetes education into the primary care practice

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.